Midatech announces priority nanoparticle patent granted by US
More specifically, this patent covers the single-step process for the self-assembly of nanoparticles that contain a central core of a noble metal surrounded by a corona of biologically relevant ligands. Such nanoparticles have a range of unique characteristics that make them ideal for applications such as targeted drug delivery and diagnostic imaging. Superparamagnetic properties also allow for thermal heating and subsequent cell apoptosis upon application of an alternating radiofrequency electromagnetic field.
"The grant of this patent represents the cornerstone of Midatech's nanotechnology IP portfolio and positions Midatech as the world leader in the development of nanoparticles for nanomedicine", commented Professor Tom Rademacher, Chairman of Midatech Group. "This affirmation of our technology by the US Patent Office puts Midatech in an extremely strong position from which to engage in high value international collaborations in order to advance our nanoparticles into the clinic".
Midatech's nanoparticles are currently being used in a number of projects including targeted drug delivery for specific diseases, oncology, siRNA delivery, targeted cell killing (through radiofrequency heating), synthetic vaccine construction and medical imaging.
Most read news
Topics
Organizations
Other news from the department research and development
Get the analytics and lab tech industry in your inbox
From now on, don't miss a thing: Our newsletter for analytics and lab technology brings you up to date every Tuesday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.